You are here

Clinical Study To Proceed With Oral Formulation of Telintra in Patients With Myelodysplastic Syndrome

PALO ALTO, Calif., Oct. 6 /PRNewswire-FirstCall/ -- Telik, Inc. (NASDAQ:TELK) announced that the company has received permission to proceed, under an Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration, with the clinical study of an oral formulation of TELINTRA(TM). The initial clinical trial will be conducted in patients with myelodysplastic syndrome (MDS) and is in addition to the ongoing clinical trial using the parenteral formulation of TELINTRA. The oral formulation of TELINTRA, if successfully developed, may permit evaluation in additional clinical indications.

TELINTRA is a novel small molecule that has been shown in preclinical testing to have myelorestorative activity when administered orally or by infusion. It was discovered using Telik's proprietary TRAP(TM) small molecule drug discovery technology.

The myelodysplastic syndromes are a group of bone marrow disorders characterized by the abnormal formation, development and maturation of blood elements. In some cases, MDS progresses to acute leukemia. There are an estimated 10,000 to 15,000 new cases of MDS diagnosed annually in the U.S., according to the American Cancer Society.

Source: Telik, Inc.

Recent Headlines

A new 'road map' might make it easier
Rationing, canceled treatments, and fearful patients
Your heart will thank you
Seems like the 2013 Guidelines are having an impact
Biomarker blood tests pick up subtle clues
Meeting 'zombie cells' along the way
Ziextenzo helps lower the incidence of febrile neutropenia
The answer may offer a potential treatment for the disease